Amylyx Pharmaceuticals has announced it will withdraw its amyotrophic lateral sclerosis (ALS) drug from the market in Canada and the U.S. following its failure in a late-stage clinical trial.
source https://www.cbc.ca/news/health/als-drug-withdrawn-relyvrio-albrioz-1.7163259?cmp=rss
No comments:
Post a Comment